What is CJC-1295?

CJC-1295 (without DAC) is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) carrying targeted amino-acid substitutions that improve its stability compared with the native peptide. Because it lacks the drug-affinity complex (DAC) of conjugated versions, it shows the pharmacokinetic behaviour typical of non-conjugated GHRH analogues in experimental settings.

Research use only. CJC-1295 is supplied strictly for in-vitro laboratory research. This page does not describe dosing, administration, or use in humans or animals, and makes no therapeutic claims.

What researchers study

In biochemical and cellular model systems, CJC-1295 binds to and activates the GHRH receptor on pituitary-derived cells, triggering intracellular signalling involved in endocrine regulation. Research has explored its receptor-binding behaviour, activation kinetics and downstream signalling under short-duration exposure conditions. As with all such peptides, observed effects vary with concentration, exposure time and experimental design, so it is used to characterise GHRH-receptor signalling rather than to infer defined physiological outcomes.

Typical research applications include:

• Analysing GHRH-receptor binding, activation and signalling dynamics
• Studying growth-hormone-axis regulation and endocrine feedback pathways
• Cellular assays evaluating transcriptional and downstream signalling responses

Studied alongside ipamorelin

A frequent theme in the literature is the pairing of a GHRH analogue with a growth-hormone secretagogue. For that reason researchers often study CJC-1295 and Ipamorelin together to compare convergent versus independent receptor signalling in the same model.

How it is supplied

CJC-1295 is supplied as a lyophilised vial with a batch-specific Certificate of Analysis (HPLC + mass spectrometry), stored refrigerated at 2–8°C.

Related reading

• New to the topic? Start with what are research peptides?